Begin main content

HPV Vaccination in Men: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: March 24, 2017
Project Number: RC0862-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of HPV vaccination for males using the quadrivalent vaccine or 9-valent vaccine for preventing HPV infection and HPV-related genital warts and cancers of the penis, anus, or oropharynx in men?
  2. What is the cost-effectiveness of HPV vaccination for males using the quadrivalent vaccine or 9-valent vaccine for preventing HPV infection and HPV-related genital warts and cancers of the penis, anus, or oropharynx in men?
  3. What are the evidence-based guidelines regarding HPV vaccination in men?

Key Message

A growing body of evidence supports the immunization of boys and young men (up to age 26), particularly with the approval of a 9V vaccine that expands the HPV types covered and additional types of cancers impacted. Recent national guidelines from Canada and the US now recommend including boys and young men in HPV immunization programs, as well as people who are immunocompromised and those with HIV. Additional evidence reviewed for this report has suggested there may be benefits to immunizing men over age 26, particularly high risk populations such as men who have sex with men, although more research is needed in this area. Economic analyses are generally favourable although are dependent on factors such as cost to purchase and administer the vaccine, and dosage schedules.